Table 3. PTLD Patient Characteristics.
| 1 | 2 | 3 | 4 | |
|---|---|---|---|---|
| Gender/Age (yr) | Male/14.8 | Female/11.9 | Male/15.2 | Male/17.6 |
| Reason for Txp | PPHTN | PHTN/CHD | BO | CF |
| Txp type | Double lung | Heart-lung | Double lung | Double lung |
| Serostatus | D+/R- | D+/R- | D+/R- | D+/R- |
| Time to PTLD (days) | 328 | 124 | 130 | 244 |
| PTLD Site | Multifocal including tonsil, adenoid, gastrointestinal, lungs and cervical lymph node | Small bowel, kidney | Right hemithorax | Ethmoid Sinus |
| PTLD type | Diffuse large B-cell lymphoma | Diffuse large B-cell lymphoma | Monomorphic | Monomorphic |
| Immunosuppression management | Decreased tacrolimus, discontinued MMF | Decreased cyclosporine, discontinued azathioprine | Tacrolimus and MMF discontinued, steroids decreased | Tacrolimus and MMF decreased |
| Additional therapy | Rituximab Chemotherapy | Rituximab Chemotherapy | Rituximab Chemotherapy | Rituximab Chemotherapy |
| Mortality 2° to PTLD | Yes |
PPHTN: primary pulmonary hypertension; PHTN/CHD: pulmonary hypertension/congenital heart disease; BO: bronchiolitis obliterans; CF: cystic fibrosis.